Chief Commercial Officer since January 2022 · AYTU BIOPHARMA, INC (AYTU)

Greg Pyszczymuka

FY2026 is the first fiscal year CompBrief holds for Greg Pyszczymuka as a named executive officer of AYTU BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2026

$558,918

Salary $434,300Stock awards $23,750

3rd of 4 named executive officers at Aytu Biopharma by FY2026 total.

4 named officers on file for AYTU BIOPHARMA, FY2026

Greg Pyszczymuka’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • AYTU’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AYTU BIOPHARMA’s whole pay program stands against its peers

  • AYTU BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AYTU→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed October 22, 2026 (DEF 14A).

Free

Get Greg Pyszczymuka’s full pay file as a PDF — free

More than this page: up to 10 years of Greg’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Greg Pyszczymuka compensation by year

AYTU BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as AYTU BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2026
Salary$434,300
Bonus$0
Stock awards$23,750
Option awards$0
Non-equity incentive$84,357
Pension and deferred compensation$0
All other$16,511
Total$558,918

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AYTU BIOPHARMA, INC DEF 14A filed October 22, 2026, accession 0001437749-26-033276, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AYTU BIOPHARMA, INC filed document, accession 0001437749-26-033276. Every figure is read from that document and cited to the page and table it appears in. Filed October 22, 2026.

Equity holdings

unvested awards at FY2026 year-end
TypeUnvested unitsValue at year-endExercise price
RSU12,500$26,875—
Option391—$1.73
Option3,322—$1.84

Per the Outstanding Equity Awards at Fiscal Year-End table in AYTU BIOPHARMA, INC's FY2026 proxy; value at the fiscal year-end close, as the company printed it.

AYTU BIOPHARMA’s named executive officers, FY2026

as the company reported each
Named executive officerRoleFY2026 total
Joshua DisbrowChief Executive Officer since April 2015$844,854
Ryan SelhornChief Financial Officer, Corporate Secretary and Treasurer since November 2024$566,212
Greg Pyszczymuka · this pageChief Commercial Officer since January 2022$558,918
Jarrett DisbrowChief Business Officer since November 2022$534,379

The full AYTU BIOPHARMA compensation record

free company brief

This page is one person within AYTU BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the AYTU BIOPHARMA proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AYTU BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Greg Pyszczymuka's compensation dossier · One-time report. No refunds.